| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | — | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Atrium Therapeutics is a biopharmaceutical company focused on delivering RNA therapeutics to the heart to address cardiomyopathies. Its development-stage candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for PRKAG2 syndrome, and ATR 1086, a siRNA-based therapy targeting PLN for PLN cardiomyopathy, with a broader pipeline aimed at genetic and cardiac diseases. The company is headquartered in San Diego, California.
| Market Cap | $196.5M | Trading Days | 1943 |
| 52W High | 73.06 |
| 52W Low | 11.36 |
| % Off High | −84.27% |
| YTD | −84.07% | 1Y | −66.75% |
| 3Y | 23.55% | 5Y | −44.65% |
| 10Y | −59.68% | Since incept. (ann.) | −3.87% |
| Ann. Volatility (1Y) | 103.67% | Ann. Volatility (3Y) | 84.67% |
| Sharpe (1Y) | −0.12 | Sharpe (3Y) | 0.69 |
| Max Drawdown (1Y) | −84.25% | Max Drawdown (3Y) | −84.25% |
| Beta (3Y, vs SPY) | 3.10 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| NERV | Minerva Neurosciences, Inc. | $195.9M | — |
| GLSI | Greenwich LifeSciences, Inc. | $197.3M | — |
| VERU | VERU INC. | $193.7M | — |
| IMRX | Immuneering Corp | $191.9M | — |
| PYXS | Pyxis Oncology, Inc. | $184.4M | — |
| WHWK | Whitehawk Therapeutics, Inc. | $183.0M | — |
| CAMP | Camp4 Therapeutics Corp | $177.6M | — |
| ANTX | AN2 Therapeutics, Inc. | $177.6M | — |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $219.9M | — |
| SIGA | SIGA TECHNOLOGIES INC | $222.3M | 9.7 |
| GALT | GALECTIN THERAPEUTICS INC | $222.6M |
| — |
| ORMP | ORAMED PHARMACEUTICALS INC. | $170.3M | 2.8 |
